Investing Upstream: How Treating Adult ADHD Could Mitigate the Approaching Dementia Crisis in the UK

1. Introduction

The demographic trajectory of the United Kingdom points towards a profound challenge for health and social care systems. As the "baby boomer" generation enters later life, the prevalence of dementia is projected to rise dramatically. Current estimates suggest that approximately 982,000 people are living with dementia in the UK, a figure expected to reach 1.4 million by 2040 [1]. The economic impact is staggering; the cost of dementia to the UK economy is forecast to be £42 billion in 2024, rising to £90 billion by 2040, with social care and unpaid family care bearing the brunt of this burden [1].

Simultaneously, the UK is experiencing a crisis in adult neurodiversity services. Despite an estimated prevalence of 2.5% to 3% in adults, ADHD remains severely underdiagnosed. An analysis of 9 million primary care records revealed that only 0.32% of the population holds an ADHD diagnosis, indicating that only 1 in 9 people living with the condition are formally recognised [2]. For those seeking help, NHS waiting lists routinely exceed two years, and in some regions extend to over a decade [3]. Consequently, the vast majority of adults with ADHD remain untreated.

Historically, these two crises (dementia in social care, and ADHD in mental health) have been treated as distinct policy silos. However, emerging longitudinal evidence suggests a direct causal link. This paper synthesises recent findings to argue that untreated adult ADHD is a significant modifiable risk factor for dementia, and that upstream investment in ADHD diagnosis and treatment could yield substantial downstream savings by reducing dementia incidence.

2. Untreated ADHD as a Modifiable Risk Factor for Dementia

The conceptualisation of ADHD has evolved from a childhood behavioural disorder to a lifelong neurodevelopmental condition with profound implications for cognitive ageing. Recent large-scale epidemiological studies have provided compelling evidence linking adult ADHD to an increased risk of neurodegenerative disease.

In a landmark nationwide cohort study of over 109,000 individuals, Levine et al. (2023) demonstrated that an adult ADHD diagnosis is associated with a nearly threefold increased risk of incident dementia (Hazard Ratio 2.77) [4]. During the 17-year follow-up period, 13.2% of adults with ADHD developed dementia, compared to only 7.0% of those without the condition [4]. Mechanistically, this association is thought to be driven by shared biological pathways, including chronic dopaminergic dysregulation, neuroinflammation, and reduced cognitive reserve [5].

Crucially, however, this elevated risk is not inevitable. Levine et al. found no clear increase in the risk of dementia among individuals with ADHD who received psychostimulant medication [4]. This finding suggests that pharmacological treatment of ADHD acts as a protective factor, potentially by normalising dopaminergic tone and enhancing cortical plasticity [5].

This distinction is vital for public health policy. It frames untreated ADHD, rather than the condition itself, as the primary risk factor. Given that the prevalence of treated ADHD in older adults is less than half of the prevalence of clinically diagnosed ADHD [6], and that overall adult diagnosis rates in the UK capture only a fraction of the true prevalence [2], a substantial population is currently ageing with untreated ADHD, placing them at an avoidable, elevated risk of cognitive decline.

3. The Economic Imperative for Upstream Intervention

The current NHS approach to adult ADHD is characterised by systemic under-resourcing, resulting in severe diagnostic bottlenecks. The independent ADHD Taskforce report highlighted that untreated ADHD costs the UK approximately £17 billion annually through lost productivity, educational drop-out, and co-occurring mental health and substance misuse issues [3]. However, this figure does not account for the long-term costs associated with increased dementia risk.

The social care sector is already buckling under the weight of current dementia demand. Approximately 70% of residents in UK care homes are living with dementia or severe memory problems [7]. The underfunding of the social care sector is estimated at £8 billion per year, a figure projected to rise to £18 billion by the end of the decade [8].

In 2024, the Lancet Commission on dementia prevention concluded that nearly half of all dementia cases globally could be prevented or delayed by addressing modifiable risk factors [9]. If untreated ADHD is integrated into public health frameworks as a modifiable risk factor, the economic argument for funding ADHD services becomes one of long-term cost avoidance.

Increasing capacity in mental health services to diagnose and treat adult ADHD requires immediate financial investment. However, this cost must be weighed against the £42 billion annual cost of dementia [1]. Preventing even a fraction of the projected 400,000 new dementia cases expected by 2040 through effective ADHD management would result in billions of pounds saved in residential care, hospital admissions, and unpaid carer burden.

4. Conclusion

The intersection of the UK's ageing population and its under-resourced adult ADHD services presents a unique public health opportunity. The evidence is clear: untreated adult ADHD significantly increases the risk of developing dementia, while appropriate pharmacological treatment appears to neutralise this risk.

By continuing to restrict access to ADHD diagnosis and treatment through underfunding and unacceptable waiting times, the UK is inadvertently compounding the future burden on its social care system. A paradigm shift is required. Investing in upstream mental health services to identify and treat adult ADHD should no longer be viewed solely as an intervention for neurodevelopmental wellbeing, but as a critical, cost-effective strategy for dementia prevention. Relieving pressure on the NHS and social care sector in the 2030s and 2040s requires proactive treatment of neurodivergent adults today.

References